Inventor
WAGTMANN NICOLAI
US14 patents
⚠️ This page may combine multiple inventors who share the name “WAGTMANN NICOLAI”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
INNATE PHARMA
9 patentsUS10329348B2Jun 25, 2019
Treatment of cancers using anti-NKG2A agents
INNATE PHARMA16 citations92
US10711063B2Jul 14, 2020
Neutralization of inhibitory pathways in lymphocytes
INNATE PHARMA8 citations83
US11572410B2Feb 7, 2023
Neutralization of inhibitory pathways in lymphocytes
INNATE PHARMA3 citations72
US11225519B2Jan 18, 2022
Treatment of cancers using anti-NKG2A agents
INNATE PHARMA3 citations71
US10870700B2Dec 22, 2020
Neutralization of inhibitory pathways in lymphocytes
INNATE PHARMA6 citations69
US11078274B2Aug 3, 2021
Siglec neutralizing antibodies
INNATE PHARMA3 citations68
US11623954B2Apr 11, 2023
Siglec-9-neutralizing antibodies
INNATE PHARMA1 citations60
US11083785B2Aug 10, 2021
Siglec-10 antibodies
INNATE PHARMA1 citations59
US11447545B2Sep 20, 2022
Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer
INNATE PHARMA0 citations49
DRAGONFLY THERAPEUTICS INC
4 patentsUS11787864B2Oct 17, 2023
Heterodimeric Fc-fused proteins
DRAGONFLY THERAPEUTICS INC13 citations83
US12384847B2Aug 12, 2025
Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen
DRAGONFLY THERAPEUTICS INC2 citations72
US12275791B2Apr 15, 2025
Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of use
DRAGONFLY THERAPEUTICS INC1 citations62
US12384851B2Aug 12, 2025
Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
DRAGONFLY THERAPEUTICS INC1 citations60